SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : A Biotech Bash - Recs and Wrecks

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: polar bear who wrote (2)8/24/1997 4:35:00 PM
From: r. peter Dale   of 171
 
PB: The SEC statement of Procept appears to be consistent with many other development stage companies: from all outward appearences its horrific. But if they are able to survive these financial difficulties, some companies prosper. I did not read the entire SEC document (very long!) nor am I familiar with Procept's products. What are the unique features of their tropical microbicide?

Procept's stock performance may serve as an example of the entire biotech field at the moment. The example I'm most familiar with is Univec - a company with real products and actual sales and a stock price chart only a blind mother could 'associate with' ('love' would be asking too much). There are many other such stories. So this appears to be time of little tolerence for risk in biotech and even less patience for R&D.

In other words, a buying opportunity. Who could disagree?

Peter
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext